Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Orchestra BioMed Holdings, Inc. - Ordinary Shares (NQ:OBIO)

5.445 -0.295 (-5.14%)
Delayed Quote Updated: 1:22 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Orchestra BioMed Holdings, Inc. - Ordinary Shares

< Previous 1 2 3 Next >
News headline image
Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026
Sessions will highlight Orchestra BioMed's collaboration with Medtronic and explore the potential for AVIM Therapy to treat hypertensive heart disease in pacemaker-indicated patients and beyond 
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Host Business Update Call on November 12, 2025
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.